The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose.
Researchers shared findings today at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. San Diego-based Dexcom said outcomes demonstrated that G7 use leads to clinically and statistically significant A1C reduction and improvement in glucose control in people with type 2 diabetes not using insulin.
Dr. Roy Beck, senior author of the study, serves as medical director of the JAEB Center for Health Research. Beck said the study represents the first and only level A evidence (the highest level of evidence graded by ADA) demonstrating strong benefits of CGM for the type 2 non-insulin population.
Earlier this year, the company shared findings showing that long-term use of the Dexcom G7 CGM supports weight management and lowers A1C for people with type 2 diabetes who aren’t on insulin therapy. Analysts said earlier this year that this population could offer a growth catalyst for Dexcom in the coming years.
“We anticipate these results will help establish a new standard of care in the U.S. and around the world,” said Jake Leach, president and CEO of Dexcom. “This is the third Dexcom sponsored randomized controlled trial that has, or will drive, Dexcom CGM to be the standard of care in people with type 2 diabetes.”
The outcomes shared by Dexcom at ADA 2026
The CONNECT study participants received diabetes education on diet and exercise at the start of the study. They also received a blood glucose meter and continued pre-study glucose-lowering medications. Half the participants used G7 and half used self-monitoring of blood glucose. The study initially screened 440 participants, of which 283 were randomized. In total, 265 completed the 26-week study.
CONNECT demonstrated clinically significant benefit for all adult type 2 non-insulin users regardless of age, gender, ethnicity, baseline A1C, body mass index, education level, income and insurance coverage. The study also showed an additional clinically significant A1C reduction with G7 alongside various combinations of current standard of care diabetes medication. Those include metformin, GLP-1s and SGLT2s.
Outcomes included an average A1C reduction with G7 of 1.6% from a baseline mean A1C of 8.8%. Participants using G7 experienced a 0.9% greater A1C reduction compared to the control. Those with an initial A1C >10% experienced, on average, a 3.1% A1C reduction, coming in 2.1% greater than the control. More than three-quarters (82%) of participants had a clinically and statistically significant lower A1C of at least 0.5%.
More than two-thirds (68%) of participants on G7 reached <7.5% A1C at 26 weeks and 46% reached < 7.0% A1C at 26 weeks. Both of these totals represented clinically and statistically significant reductions. The use of G7 alone lowered A1C more than any other medication treatment group (2.4% vs. 1.5%). Additionally, using G7 had an additive effect in lowering A1C across all medication groups.
Time in range (70 to 180 mg/dL) came in five hours per day greater for G7 users compared to the control. Those using G7 observed a clinically significant time in range improvement as early as 1-4 weeks and sustained it through 26 weeks. On average, after 26 weeks, G7 users achieved 62% time in range, compared to 41% in the control. Those using G7 reported greater satisfaction than the control as well.
A six-month extension phase of CONNECT is currently ongoing. Dexcom expects further data on G7 benefits out to 12 months.
